专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

EP2083819A2 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS 有权转让
标题翻译： PDE10抑制剂和相关组合物和方法
公开(公告)号：EP2083819A2
公开(公告)日：2009-08-05
申请号：EP07845135.8
申请日：2007-11-21
申请人： Omeros Corporation
发明人： CUTSHALL, Neil S. , JOHNSTON, Derek , UROGDI, Lazlo , BERGMANN, John E. , ONRUST, Rene , HONGKUI, Zeng , CSEH, Sandor , PAPP, Akos
IPC分类号： A61K31/404 , A61K31/4184 , A61K31/4402 , A61K31/47 , A61K31/4965 , A61K31/517 , A61K31/542 , C07D215/12 , C07D235/08 , C07D235/10 , A61P25/18
CPC分类号： A61K31/404 , A61K31/4184 , A61K31/4402 , A61K31/47 , A61K31/4965 , A61K31/517 , A61K31/542 , C07D215/36 , C07D235/28
摘要： Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: (I) wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

52. 发明授权

EP1246573B1 SOFT TISSUE STRUCTURE REPAIR USING ADHESIVE 有权
标题翻译：软组织修复使用水泥
公开(公告)号：EP1246573B1
公开(公告)日：2008-12-10
申请号：EP00989482.5
申请日：2000-12-22
申请人： Omeros Corporation
发明人： DEMOPULOS, Gregory, A. , REED, Scott, W. , BACHMAN, Alan, B. , KARL, Frederick, T. , ALLEN, William, J. , ADAMS, Leland, R. , THATCHER, Lawrence, G.
IPC分类号： A61B17/08 , A61B17/11
CPC分类号： A61B17/1146 , A61B17/00491 , A61B17/064 , A61B2017/00004 , A61B2017/0609 , A61B2017/0647
摘要： A reinforcing member or stent (7) is inserted into opposite end portions (1, 1') of a lacerated tendon and secured within the tendon by adhesive so that tension applied to the tendon is transmitted across the laceration by way of the reinforcing member (7).

53. 发明公开

EP1609477A1 Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure 失效
标题翻译： Bespüllungslösung及其在血管结构为疼痛，炎症和/或痉挛围手术期抑制使用
公开(公告)号：EP1609477A1
公开(公告)日：2005-12-28
申请号：EP05076510.6
申请日：1995-12-12
申请人： Omeros Corporation
发明人： Demopulos, Gregory , Pierce, Pamela Anne , Herz, Jeffrey M.
IPC分类号： A61K38/08 , A61K38/55 , A61K38/06 , A61K38/12 , A61K45/06 , A61K31/00 , A61K9/08 , A61P41/00 , A61K31/4196 , A61K31/135 , A61K31/437 , A61K31/407 , A61K31/4409 , A61K31/4412 , A61K31/5375 , A61K31/5415
CPC分类号： A61K38/08 , A61K9/0019 , A61K9/08 , A61K31/00 , A61K31/135 , A61K31/352 , A61K31/4045 , A61K31/407 , A61K31/4164 , A61K31/4168 , A61K31/4174 , A61K31/4196 , A61K31/437 , A61K31/439 , A61K31/4406 , A61K31/4409 , A61K31/4412 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/48 , A61K31/498 , A61K31/506 , A61K31/5375 , A61K31/538 , A61K31/5415 , A61K38/04 , A61K38/043 , A61K38/12 , A61K38/22 , A61K38/57 , A61K45/06 , Y10S977/904 , A61K2300/00
摘要： A method and solution for perioperatively inhibiting a variety of pain and inflammation and spasm processes at a vascular structure during an intervascular procedure. The solution includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents in a physiologic base, such as saline or lactated Ringer's solution. Depending on the application, the pain and inflammation agents included in the solution may include: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists: (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin 1 and neurokinin 2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachadonic acid metabolites, including (a) phospholipase inhibitors, including PLA 2 isoform and PLCγ isoform inhibitors, (b) cyclooxygenase inhibitors, and (c) lipooxygenase inhibitors; (10) prostanoid receptor antagonists including eicosanoid EP-1 and EP-2 receptor subtype antagonists and thromboxane receptor subtype antagonists; (11) leukotriene receptor antagonists including leukotriene B 4 and D 4 receptor subtype antagonists; (12) opioid receptor agonists, including mu-opiate, delta-opiate, and kappa-opiate receptor subtype agonists; (13) purinoceptor agonists and antagonists including P 2X receptor antagonists and P 2Y receptor agonists; (14) adenosine triphosphate (ATP) sensitive potassium channel openers; and (15) calcium channel antagonists. Suitable anti-inflammatory/anti-pain agents which also act as anti-spasm agents include serotonin receptor antagonists, tachykinin receptor antagonists, ATP-sensitive potassium channel openers and calcium channel antagonists. Other agents which may be utilized in the solution specifically for their anti-spasm properties including endothelin receptor antagonists and the nitric oxyde donors (enzyme activators). The solution is used to continuously irrigate a wound during an operative/interventional procedure for preemptive inhibition of pain and inflammation, as well as vascular and smooth muscle spasm, while avoiding undesirable side effects associated with oral, intramuscular or intravenous application of larger doses of the agents. The solution is useful for intravascular procedures.
摘要翻译：一种用于在手术前后抑制在帧间血管过程期间的各种疼痛和血管结构的炎症和痉挛过程的方法和溶液。该解决方案包括多个疼痛和炎症抑制剂，并在生理基痉挛抑制剂，颜色：如盐水或乳酸林格氏溶液。取决于应用，包括在溶液中的疼痛和炎症的药剂可包括：（1）血清素受体拮抗剂; （2）血清素受体激动剂; （3）组胺受体拮抗剂; （4）血管舒缓激肽受体拮抗剂：（5）激肽释放酶抑制剂; （6）速激肽受体拮抗剂，包括neurokinin1和neurokinin2受体亚型拮抗剂; （7）降钙素基因相关肽（CGRP）受体拮抗剂; （8）白介素受体拮抗剂; （9）活性在花生四烯酸代谢物，包括（a）磷脂酶抑制剂，包括同工型PLA2和PLC伽马同种型抑制剂，（b）中环加氧酶抑制剂，和（c）脂氧合酶抑制剂的合成途径中的酶的抑制剂; （10）前列腺素受体拮抗剂，包括类花生酸EP-1和EP-2受体亚型拮抗剂和凝血恶烷受体亚型拮抗剂; （11）白三烯受体拮抗剂，包括白三烯B4和D4受体亚型拮抗剂; （12）阿片样物质受体激动剂，μ-阿片包括，δ-阿片，和κ阿片受体亚型激动剂; （13）嘌呤受体激动剂和拮抗剂，包括P2X受体拮抗剂和P2Y受体激动剂; （14）三磷酸腺苷（ATP）通道开放剂敏感的钾离子; 和（15）钙通道拮抗剂。合适的抗炎/抗疼痛剂，其因此用作抗痉挛剂包括血清素受体拮抗剂，速激肽受体拮抗剂，ATP敏感性钾通道开放剂和钙通道拮抗剂。可以在溶液中专门为它们的抗痉挛性质，包括内皮素受体拮抗剂和机器制造业用的硝酸供体（酶激活剂）可以使用其它试剂。该溶液被用于在用于治疗疼痛和炎症的先发制人的抑制，以及血管和平滑肌痉挛手术/介入过程期间连续冲洗伤口，同时避免与口服，肌注或更大剂量的静脉内应用相关联的不期望的副作用代理商。该解决方案是血管内的程序非常有用。

54. 发明公开

EP1531757A2 BIODEGRADABLE TRIBLOCK COPOLYMERS, SYNTHESIS METHODS THEREFOR, AND HYDROGELS AND BIOMATERIALS MADE THERE FROM 有权转让
标题翻译：可生物降解的三嵌段共聚物的合成方法和DAF [R水凝胶和由其制成的生物材料
公开(公告)号：EP1531757A2
公开(公告)日：2005-05-25
申请号：EP03765759.0
申请日：2003-07-18
申请人： Omeros Corporation , Institute of Materials Research and Engineering
发明人： LI, Jun , LI, Xu , NI, Xiping , LEONG, Kam, W.
IPC分类号： A61F2/00
CPC分类号： A61K9/0024 , A61K9/1075 , A61K9/5153 , A61K47/32 , A61K47/34 , A61K47/6903 , A61K47/6951 , A61L27/34 , A61L27/52 , A61L27/54 , A61L31/10 , A61L31/145 , A61L31/16 , A61L2300/602 , A61L2300/802 , B82Y5/00
摘要： A drug delivery system that includes a hydrogel formed from cyclodextrin and an amphiphilic copolymer that includes an A polymer block comprising a poly(alkylene oxide) and a B polymer block comprising a poly(hydroxyalkanoate), and a therapeutically effective amount of at least one therapeutic agent intimately contained within the hydrogel. In one preferred embodiment of the invention, the A polymer block 10 is poly(ethylene oxide) (PEO) and the B polymer block is poly[(R)-3-hydroxybutyrate] (PHB), and the copolymer is the triblock ABA copolymer PEO-PHB-PEO. A method of synthesizing the amphiphilic triblock copolymer is also provided.

55. 发明公开

EP1227807A2 IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION 有权
标题翻译：冲洗溶液和用于抑制疼痛和炎症的方法
公开(公告)号：EP1227807A2
公开(公告)日：2002-08-07
申请号：EP99956629.2
申请日：1999-10-20
申请人： Omeros Corporation
发明人： DEMOPULOS, Gregory, A. , PALMER, Pamela, P. , HERZ, Jeffrey, M.
IPC分类号： A61K31/18 , A61K31/415 , A61K31/495 , A61K31/55 , A61K31/535 , A61P23/02
CPC分类号： A61K31/444 , A61K31/00 , A61K31/18 , A61K31/352 , A61K31/4164 , A61K31/4168 , A61K31/4174 , A61K31/439 , A61K31/4406 , A61K31/4427 , A61K31/4439 , A61K31/498 , A61K31/538 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at leat one α2-receptor agonist from the group consisting of clonidine; dexmedetomidine; oxymetazonline; (R)-(-)-3'-(2-amino-1-hydroxyethyl)-4'-fluoro-methanesulfoanilide; 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline; AGN 191103; AGN 192172; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK14304); 5,6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine (BHT920); 6-ethyl-5,6,7,8-tetrahydro-4H-oxaazolo[4,5-d]azepin-2-amine; and 5,6-dihydroxyl-1,2,3,4-tetrahydro-1-naphyl-imidazoline, and optionally, additional multiple pain and inflammation inhibitory agents at dilute concentration like a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin1 antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin1 antagonist, a bradykinin2 antagonist and a $(g)m-opioid agonist. The solution is applied by continous irrigation of a wound during a surgical procedure for preemptive inhibition of pain. The solution is applied b continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain.

56. 发明公开

EP4275752A2 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS 审中-实审
公开(公告)号：EP4275752A2
公开(公告)日：2023-11-15
申请号：EP23191932.5
申请日：2011-11-07
申请人： Omeros Corporation
发明人： DEMOPULOS, Gregory, A. , GAITANARIS, George, A.
IPC分类号： A61P25/30
摘要： This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

58. 发明公开

EP3964233A1 METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-实审
公开(公告)号：EP3964233A1
公开(公告)日：2022-03-09
申请号：EP21188935.7
申请日：2012-04-06
申请人： University of Leicester , Omeros Corporation
发明人： DEMOPULOS, Gregory A. , DUDLER, Tom , SCHWAEBLE, Hans-Wilhelm
IPC分类号： A61K39/395 , C12N15/11 , C07K16/40
摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

59. 发明公开

EP3878865A3 COMPOSITIONS AND METHODS OF INHIBITING MASP-1 AND/OR MASP-2 AND/OR MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS 审中-公开
公开(公告)号：EP3878865A3
公开(公告)日：2021-12-08
申请号：EP21152111.7
申请日：2013-06-18
申请人： Omeros Corporation , University of Leicester
发明人： Schwaeble, Hans-Wilhelm , Demopulos, Gregory A. , Dudler, Thomas , Gray, Patrick
IPC分类号： C07K16/18 , C07K16/40 , A61K39/00 , A61K45/06
摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

60. 发明公开

EP3908601A1 METHODS AND COMPOSITIONS FOR TREATING CANCER 审中-实审
公开(公告)号：EP3908601A1
公开(公告)日：2021-11-17
申请号：EP20739226.7
申请日：2020-01-10
申请人： Omeros Corporation
发明人： CICIRELLI, Michael , CUTSHALL, Neil, S. , DEMOPULOS, Gregory, A. , GAITANARIS, George, A. , GAVIN, Marc, A. , GRAGEROV, Alexander , LITTLE, Thomas, L. , ONRUST, Rene
IPC分类号： C07K14/705 , C07K14/54 , A61K35/17

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式